Transbuccal insulin - MidaSol

Drug Profile

Transbuccal insulin - MidaSol

Alternative Names: Insulin - MidaSol; Insulin buccal soluble film - Midatech Pharma; Insulin nanoparticles buccal film - Midasol; MidaForm insulin PharmFilm; MidaForm™-Insulin-Pharmfilm®; MSL-001; MSRX-301; MTD-101; Nanoparticle insulin

Latest Information Update: 05 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MidaSol Therapeutics; Midatech; MonoSol Rx
  • Developer MidaSol Therapeutics
  • Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus

Most Recent Events

  • 27 Jul 2015 Phase-II clinical trials in Type-1 diabetes mellitus in Australia (Buccal) (ACTRN12615000495527)
  • 01 Jul 2015 Midatech and Monosol plan a phase II trial Type-I diabetes mellitus in Australia (ACTRN12615000495527)
  • 24 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top